Clinical Trial Update: A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) [Phase 2]

View source ↗

Summary

Phase 2 study of Tarceva (Erlotinib) in locally advanced or metastatic non-squamous non-small cell lung cancer completed; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-10-29